Diagnostics for the Real World (DRW)
Diagnostics for the Real World (DRW) is dedicated to developing high-performance, easy-to-use point-of-care diagnostics to address serious infectious diseases, especially in resource-limited settings. Their mission is to provide innovative solutions that support clinical services for people in real need, with a focus on rapid, accurate testing that can be used in diverse environments. DRW's technology, including the SAMBA platform, has been recognized for its impact during the COVID-19 pandemic and continues to advance diagnostics for infectious diseases worldwide.
Industries
Nr. of Employees
medium (51-250)
Diagnostics for the Real World (DRW)
Science Village, Chesterford Research Park, Little Chesterford, CB10 1XL, UK
Patents
Apparatus and method for automated sample preparation and adaptor for use in the apparatus
US-10330694-B2
View Details
Apparatus and method for automated sample preparation and adaptor for use in the apparatus
US-10330694-B2
View DetailsProducts
Portable automated point‑of‑care molecular diagnostic system
A fully automated near‑patient instrument that performs sample extraction, nucleic acid amplification and lateral‑flow detection to deliver rapid molecular test results in under an hour without need for central laboratory infrastructure.
Multiplex respiratory virus molecular tests (one‑sample, multi‑target)
Nucleic‑acid amplification tests configured to detect and differentiate multiple respiratory viruses (examples reported: SARS‑CoV‑2 with Influenza A/B; SARS‑CoV‑2 with RSV) from a single swab.
Portable automated point‑of‑care molecular diagnostic system
A fully automated near‑patient instrument that performs sample extraction, nucleic acid amplification and lateral‑flow detection to deliver rapid molecular test results in under an hour without need for central laboratory infrastructure.
Multiplex respiratory virus molecular tests (one‑sample, multi‑target)
Nucleic‑acid amplification tests configured to detect and differentiate multiple respiratory viruses (examples reported: SARS‑CoV‑2 with Influenza A/B; SARS‑CoV‑2 with RSV) from a single swab.
Services
Onboarding, technical support and operator training to enable deployment and ongoing operation of near‑patient molecular diagnostic systems.
Provision of open‑access materials and resources to support local implementation and evaluation of point‑of‑care molecular tests.
Commercial and distributor engagement to supply instruments and tests to healthcare providers and laboratories in defined markets.
Onboarding, technical support and operator training to enable deployment and ongoing operation of near‑patient molecular diagnostic systems.
Provision of open‑access materials and resources to support local implementation and evaluation of point‑of‑care molecular tests.
Commercial and distributor engagement to supply instruments and tests to healthcare providers and laboratories in defined markets.
Expertise Areas
- Point-of-care molecular diagnostics
- Multiplex respiratory assay development
- Clinical validation and implementation studies
- Rapid outbreak-response assay development
Key Technologies
- Isothermal nucleic acid amplification
- Lateral‑flow molecular detection
- Automated sample‑in result‑out instrument systems
- Multiplex nucleic acid assays
News & Updates
The SAMBA II point-of-care diagnostic device was donated to the Science Museum Group and is part of an extensive COVID-19 collection, highlighting its impact during the pandemic.
The SAMBA II system played a crucial role in COVID-19 testing at Winchester College, helping reduce the time in COVID wards and enabling faster clinical decisions.
DRW achieved UK technical validation for two multiplex respiratory virus tests on the SAMBA II platform, enabling rapid detection of SARS-CoV-2, Flu A/B, and RSV.
The SAMBA II point-of-care diagnostic device was donated to the Science Museum Group and is part of an extensive COVID-19 collection, highlighting its impact during the pandemic.
The SAMBA II system played a crucial role in COVID-19 testing at Winchester College, helping reduce the time in COVID wards and enabling faster clinical decisions.
DRW achieved UK technical validation for two multiplex respiratory virus tests on the SAMBA II platform, enabling rapid detection of SARS-CoV-2, Flu A/B, and RSV.